Abstract
We have shown that glycemic control prevents diabetes‐mediated remodeling of the cerebrovasculature. However, whether the remodeling can be reversed is unknown. Given that angiotensin II Type 1 receptor blockers (ARBs) reverse pathological vascular remodeling and function independent of changes in blood pressure in other vascular beds, we hypothesized that azilsartan medoxomil, a new ARB, reverses cerebrovascular remodeling in diabetes independent of blood pressure.MethodsControl Wistar and diabetic Goto‐Kakizaki rats (n=20/group), were treated with vehicle (water) or Azilsartan medoxomil (3 mg/kg/day) from 18 to 22 weeks of age. Blood glucose and blood pressure was monitored and middle cerebral artery structure and function was evaluated using pressurized arteriography.ResultsBlood glucose was higher in the GK compared to Wistar rats. Azilsartan treatment lowered blood glucose. There was no difference in blood pressure among the groups. Diabetic animals exhibited lower myogenic tone, increased wall thickness, and cross sectional area compared to controls which were corrected by azilsartan treatment.ConclusionAzilsartan medoxomil restores diabetes‐induced cerebrovascular remodeling independent of blood pressure. This effect may be partially mediated by improvement of blood glucose. Disclosure The project is supported by Takeda Pharmaceuticals North America Inc.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
